For several years the ID17 Biomedical beamline at the ESRF has developed synchrotron radiation therapy preclinical programmes to treat aggressive brain tumours. Two techniques have been developed at the ESRF: a) The Microbeam Radiation Therapy (MRT) using spatially fractionated "white beam" (energies 50-300 keV) irradiation (beam widths 25-100 μm, spacing between beams 200-400 μm ) with extremely high dose rates (up to about 20 kGy/s) and depositing very high doses (300-1000 Gy) in the targeted tissue. b) The Stereotactic Synchrotron Radiation Therapy (SSRT) using spatially homogeneous monochromatic beam with the energy closely above that of the K-edge of a contrast- or chemotherapeutical agent (iodine, gadolinium, platinum) loaded into the tumour volume for obtaining a dose-enhancement. In 2005 an International review panel of oncology experts has recommended to move to clinical trials on humans in SSRT and on large animals in MRT. The works required for this program were launched in autumn 2007 with constructing a new, dedicated experimental hutch for MRT and a major upgrade of the existing sample-positioning station to a patient-positioning station for SSRT. In parallel, safety systems are developed and progressively implemented and a patient treatment-planning system developed. © 2010 American Institute of Physics.

Requardt, H., Bravin, A., Prezado, Y., Bräuer-Krisch, E., Renier, M., Brochard, T., et al. (2010). The Clinical Trials Program at the ESRF Biomedical Beamline ID17: Status and Remaining Steps. In The 10th international conferece on synchrotron radiation instrumentation (pp.161-164) [10.1063/1.3463164].

The Clinical Trials Program at the ESRF Biomedical Beamline ID17: Status and Remaining Steps

Bravin A
Secondo
Membro del Collaboration Group
;
2010

Abstract

For several years the ID17 Biomedical beamline at the ESRF has developed synchrotron radiation therapy preclinical programmes to treat aggressive brain tumours. Two techniques have been developed at the ESRF: a) The Microbeam Radiation Therapy (MRT) using spatially fractionated "white beam" (energies 50-300 keV) irradiation (beam widths 25-100 μm, spacing between beams 200-400 μm ) with extremely high dose rates (up to about 20 kGy/s) and depositing very high doses (300-1000 Gy) in the targeted tissue. b) The Stereotactic Synchrotron Radiation Therapy (SSRT) using spatially homogeneous monochromatic beam with the energy closely above that of the K-edge of a contrast- or chemotherapeutical agent (iodine, gadolinium, platinum) loaded into the tumour volume for obtaining a dose-enhancement. In 2005 an International review panel of oncology experts has recommended to move to clinical trials on humans in SSRT and on large animals in MRT. The works required for this program were launched in autumn 2007 with constructing a new, dedicated experimental hutch for MRT and a major upgrade of the existing sample-positioning station to a patient-positioning station for SSRT. In parallel, safety systems are developed and progressively implemented and a patient treatment-planning system developed. © 2010 American Institute of Physics.
Si
paper
Biomedical Instrumentation; Brain tumours; Clinical Trials; Microbeam Radiation Therapy; Stereotactic Synchrotron radiation Therapy;
English
10th International Conference on Synchrotron Radiation Instrumentation, SRI 2009
978-073540782-4
2010
Requardt, H., Bravin, A., Prezado, Y., Bräuer-Krisch, E., Renier, M., Brochard, T., et al. (2010). The Clinical Trials Program at the ESRF Biomedical Beamline ID17: Status and Remaining Steps. In The 10th international conferece on synchrotron radiation instrumentation (pp.161-164) [10.1063/1.3463164].
Requardt, H; Bravin, A; Prezado, Y; Bräuer-Krisch, E; Renier, M; Brochard, T; Berkvens, P; Estève, F; Elleaume, H; Adam, J; Blattmann, H; Laissue, J; Kaser-Hotz, B; Nemoz, C; Berruyer, G
File in questo prodotto:
File Dimensione Formato  
requardt_AIP_2010.pdf

Solo gestori archivio

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 274.52 kB
Formato Adobe PDF
274.52 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/342342
Citazioni
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
Social impact